WELCOME TO THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER
BASL2020 will be a virtual event and run from 21st -23rd September 2020. Registration is now open. Abstract submission closes at 09:00hrs on 1st July. Visit the BASL Events webpage for more information.
BASL2020 VIRTUAL ANNUAL MEETING
21st - 23rd September - registration open
We are delighted to announce that registration for the BASL Virtual Annual Meeting is open. Note the Change of Date to Monday 21st - Wednesday 23rd September, the programme sessions will be held across the afternoons of the 3 days. Abstract submission closes at 09:00 on Wednesday 1st July. A virtual programme will be announced soon on the BASL Events webpage.
BASL ANNUAL MEETING
BASL AND BASL SUB-GROUPS
The British Association for the Study of the Liver is a multi-disciplinary society with around 900 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions.
British Liver Nurse Association is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.
The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.
The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development. The BLTG will foster close relationships with BTS (British Transplant Society) and LICAGE (Liver Intensive Care Group of Europe) and will build on the role of the UK and Ireland Annual Meeting by delivering structure and authority to the group.
Is a professional pharmacy organisation aiming to develop knowledge and understanding of liver disorders including viral hepatitis, in order to improve the quality of patient care, through medicines optimisation, collaborative and multi-disciplinary working and promoting patient-focused research.
HCC UK is a multi-disciplinary organisation aiming to promote collaboration in research, education and clinical service development for primary liver cancer. We bring together leading oncologists, liver surgeons, hepatologists, basic scientists, radiologists, pathologists and specialist nurses to lead improvement in the quality of patient care.
Gilead Sciences Global Grant Program Supporting Investigator-Sponsored Research in COVID-19: COMMIT™Read more
Gilead Sciences Global Grant Program Supporting Investigator-Sponsored Research in COVID-19: COMMIT™ (COvid-19 unMet MedIcal needs and
associated research exTension)
In an effort to further address the unmet medical need in COVID-19, Gilead Medical Affairs is launching the COMMIT program.
Gilead will consider support for research proposals that meet one of the following criteria:
• Expand data on clinical course and outcome in vulnerable populations
• Long-term sequelae
• Real world safety and effectiveness of remdesivir used alone or with other agents.
Projects from across the world will be considered for research grants of up to 250,000 USD each. Gilead will not consider proposals that request COVID-19 screening costs (including test kits) or proposals that request remdesivir or other study drug.
Applications will be accepted from 1st July to 3rd August 2020.
For more information on Gilead Sciences 2020 COMMIT program and how to apply, please visit: https://www.gilead.com/science-and-medicine/research/investigator-sponsored-research/covid19-commit-rfp .
Dame Sheila Sherlock Research Prize 2020 - Applications OpenRead more
Each year BASL presents the Dame Sheila Sherlock research prize, one of the highlights of the annual meeting. This prize is awarded annually to recognise the enormous contribution of Dame Sheila Sherlock to the development of Hepatology as a discipline in its own right.
Dame Sheila was involved in the foundation of the British Liver Club in 1961, which subsequently evolved into The British Association for the Study of the Liver (BASL). She was one of our past presidents and the first recipient of The BASL Distinguished Service Award. In keeping with Dame Sheila’s enthusiasm for fostering young researchers, this eponymous research prize is awarded to young investigators without substantive posts in either medicine or science for their research contributions in the field of Hepatology.
The winner will receive free registration to the meeting, an award and a prize of £1,000 and an invite to deliver the prize lecture at the BASL Virtual Annual Meeting on 21st - 23rd September 2020.
To apply, please send one A4 sheet outlining your research and another A4 sheet listing up to 5 related publications.
Please send submissions to email@example.com before the deadline of 09:00hrs on Monday 3rd August 2020.
The Andy Burroughs Young Investigator Award - Applications OpenRead more
The Andy Burroughs Young Investigator Award was set up in honour of the late Professor Andrew Burroughs.
Professor Burroughs was an eminent and world renowned Professor of Hepatology and Consultant Physician/Hepatologist and among his many achievements include his wide area of expertise in cirrhosis and portal hypertension and significant contribution to liver Transplantation.
This prize is awarded to young investigators who have contributed to clinical or translational research related to liver disorders who are in training or within 2 years of taking up consultant positions (or equivalent); this year the winner will receive free registration to the meeting, an award and a prize of £1,000 and an invite to deliver the prize lecture at the BASL Virtual Annual Meeting on 21st - 23rd September 2020.
To apply, please send one A4 sheet outlining the research and another A4 sheet listing up to 5 related publications.
Please send submissions to firstname.lastname@example.org before the deadline of 09:00hrs on Monday 3rd August 2020.
High COVID-19 mortality rates among those with liver disease, study findsRead more
A new international study has found high mortality rates from COVID-19 among people with chronic liver disease and cirrhosis.
The researchers, led by teams at Oxford University Hospitals NHS Foundation Trust and the University of North Carolina, set up an international registry to collect clinical details of patients with chronic liver disease and cirrhosis who develop COVID-19.
Between 25 March 2020 and 20 April 2020, 152 cases were submitted to the registry, over 95 percent of which were hospitalised. Patients with cirrhosis had poor outcomes with an overall death rate of 40 percent. Those with advanced disease called ‘decompensated cirrhosis’ had the highest rate of death (between 43 and 63 percent), compared with 12 percent for patients with liver disease but without cirrhosis.
The paper has been published online by the Journal of Hepatology.
Dr Thomas Marjot, who leads the project alongside Dr Gwilym Webb and Professor Ellie Barnes at the Translational Gastroenterology Unit at Oxford’s John Radcliffe Hospital, said: “Until now, very little was known about the impact of COVID-19 on patients with pre-existing liver disease.
“Our data, which were gathered from 21 countries, show that people with liver disease, and especially those with decompensated cirrhosis, have particularly poor outcomes once they develop COVID-19.
“Even when other risk factors for poor outcomes - such as age, obesity, diabetes and high blood pressure - were taken into account, the severity of baseline liver disease was still associated with increased mortality,” he explained.
The study also showed that many patients with cirrhosis and COVID-19 developed features of worsening liver function (encephalopathy, ascites, bleeding), and in 24 percent of cases this occurred even without any chest symptoms or breathing difficulties.
However, Dr Marjot explained, these preliminary findings should be interpreted with caution: “our study is limited by selection bias; this is when doctors tend to report more severe cases with the worst outcomes. Many patients with cirrhosis and COVID-19 who have good outcomes will therefore not be included in the registry.”
“Nonetheless, these findings do suggest high death rates with COVID-19 in patients with cirrhosis and that contracting the virus may lead to a deterioration in liver function. Therefore, anyone coming into hospital with worsening symptoms of liver disease should be considered for coronavirus testing”.
Pamela Healy, Chief Executive of the British Liver Trust said: “This important study demonstrates the devastating impact of coronavirus on liver patients. We are asking the Government to quickly review the shielding guidance and ensure that those with the most severe forms of liver disease have clear advice and support. Whilst lockdown may be easing for many of us, these patients often have multiple complex problems and urgently need clarity and to remain protected.”
Roy Probert, Senior Communications Manager
Tel: 01865 223070
Mobile: 07747 456443
Job Advert - Clinical Fellow (Higher-Senior) in Hepatology, CambridgeRead more
Clinical Fellow (Higher-Senior) in Heptology - Cambridge
Job ref: 180-CFH-3338
Read more on the Cambridge University Hospitals website > https://www.careers.cuh.nhs.uk/current-vacancies/?_ts=1#!/job/v2400264
Main area: Hepatology and Liver Transplantation
Grade: Clinical Fellow (Higher-Senior)
Contract: Fixed term
Hours: Full Time
Employer: Cambridge University Hospitals NHS Foundation Trust
Site: Addenbrooke's Hospital Cambridge
Salary: £49,036 per annum (Higher), £51,069 per annum (Senior)
Closing date: 31/05/2020 23:59
27/08/20 - 29/08/20
Given the continuing impact of the SARS-CoV-2 pandemic and ongoing restrictions, EASL has decided to transition the onsite International Liver Congress™ 2020, planned for 25–28 August, to an immersive and exciting digital event –The Digital International Liver Congress™ 2020 which will be held 27–29 August 2020.
Since 2019, EASL has been livestreaming all sessions at its events and has been providing educational content online through the EASL Campus. This experience of delivering online content to the liver community will now be stepped up to the next level at The Digital International Liver Congress™ 2020.
The Digital ILC 2020 will provide the liver community with an exciting opportunity to connect and to share the latest in data, science, and education.
Visit the International Liver Congress™ 2020 website for full information and registration details.
For the latest news, sign up to the ILC newsletter.
21/09/20 - 23/09/20
The BASL Committee has decided to address today’s global challenge, and to ensure that members are offered continuing education during 2020, by developing a virtual Annual Meeting platform.
A virtual meeting will continue to provide the essential education that BASL members value and see it as a vital benefit to their membership.
In light of the COVID-19 global impact, this is the perfect opportunity for the liver care community to come together and share knowledge and collaborate through a virtual platform.
The BASL2020 Virtual Annual Meeting is shaping up to be an exciting event with world class speakers across a range of multi-disciplinary topics and the programme is nearly complete and will be published very soon.
REGISTRATION IS OPEN - click on the link > HERE.
Visit the BASL News webpage to find out how to apply for the Dame Sheila Sherlock Research Prize and Andy Burroughs Young Investigator Award.
We very much hope that our members will be able to join us for this year's BASL Annual Meeting.
Please contact email@example.com if you have any questions.
24/09/20 - 25/09/20
CCA-UK is to hold a clinical themed workshop on the morning of Thursday 24th September 2020 at the UK Oncology Forum Annual Conference.
The UK Oncology Forum annual conference runs from 24-25th September and both the CCA-UK workshop and UK Oncology Forum Conference are free to attend. The meeting will run in a virtual format.
Please find the invitation to follow > Download 2020 OF Invitation CCA-UK.pdf
Download a workshop programme > Download Programme CCA-UK Workshop UK Onc Forum_24.9.20.pdf
Anyone wishing to attend the CCA-UK workshop will be expected to stay on for the whole of day one of the conference.
Registration is via the UK Oncology Forum - https://oncology-forum.co.uk/ . When registering please ensure you choose the CCA-UK workshop option under the section UK Oncology Forum and Cancer Collaboration. Delegates are of course welcome to attend both days of the UK Oncology Forum Conference.
Save the Date
This year the BLNA September meeting will take place as a virtual forum on the afternoon of Friday 25th September.
The programme will include:
- Educational presentations
- Poster presentations
- Live Q&A
An interactive afternoon is planned that will allow liver nurses to participate in educational content, share information and network.
Following the COVID-19 pandemic the BLNA would like to encourage the liver nurse community to participate in a dedicated event to discuss challenges, share knowledge and deliberate the changed healthcare landscape.
Further details will follow.
15/10/20 - 17/10/20
Save the Date
Turkish and British Associations for the Study of the Liver (TASL-BASL) are pleased to announce a monothematic conference, “Drug-induced Liver Injury: Unresolved questions and unmet needs” in Istanbul, Turkey, on October 15-17, 2020. We hope that the programme will be a timely and welcome opportunity to reflect upon an area of critical importance for clinicians, researchers, scientists, pharma and other health care professionals.
Invitation letter > Download Letter for TASL-BASL Final.pdf
Further details including a draft programme and how to register for the conference will follow.